Last checked at 7 Jan 2011 11:30
OXFORD BIOMEDICA PLC("Oxford BioMedica" or the "Company")
GENERAL MEETING
Oxford BioMedica (LSE: OXB), a biopharmaceutical company developing gene-based medicines and therapeutic vaccines, announces that all resolutions proposed were duly passed at its General Meeting, held today in London.
The full text of all the resolutions can be viewed in the Notice of Meeting by visiting the Company's website at www.oxfordbiomedica.co.uk (located on pages 156 to 158 of the prospectus dated 13 December 2010).
In accordance with the Company's obligations under Listing Rule 9.6.2, copies of the resolutions passed at the General Meeting have been submitted to the National Storage Mechanism and will shortly be available for viewing at http://www.hemscott.com/nsm.do.
The results of the proxy voting in advance of the meeting are shown below. On the Record Date (10 December 2010) there were 544,875,557 1p ordinary shares in issue, each carrying one vote per share.
Resolution |
Votes For | Votes at Chairman's Discretion | Votes at other proxy Discretion |
Votes Against |
Votes Withheld |
Total votes cast | Result |
Ordinary resolutions | |||||||
1 | 165,363,035 | 602,268 | 379,129 | 92,215 | 786,126 | 166,436,647 | Passed |
2 | 165,123,318 | 862,721 | 379,129 | 53,468 | 804,137 | 166,418,636 | Passed |
4 | 97,441,672 | 648,135 | 379,129 | 160,484 | 68,593,353 | 98,629,420 | Passed |
5 | 165,096,664 | 657,295 | 379,129 | 199,525 | 890,160 | 166,332,613 | Passed |
Special resolution | |||||||
3 | 164,846,001 | 640,898 | 379,129 | 416,975 | 939,770 | 166,283,003 | Passed |
-Ends-
For further information, please contact: | |
Oxford BioMedica plc: John Dawson, Chief Executive Officer |
Tel: +44 (0)1865 783 000 |
Singer Capital Markets Limited Shaun Dobson/ Claes Spång |
Tel: +44 (0)20 3205 7500 |
Media/Financial Enquiries: Emma Thompson/Rob Newman/Amber Bielecka M:Communications |
Tel: +44 (0)20 7920 2345
|
US Enquiries: Simon Harnest The Trout Group LLC |
Tel: +1 (646) 378 2900 |
Notes to editors
1. Oxford BioMedica
Oxford BioMedica (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient gene delivery system (LentiVector®), which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline and its partners include sanofi-aventis, Sigma-Aldrich and Pfizer. Technology licensees include Biogen Idec, GlaxoSmithKline, Merck & Co and Pfizer. Further information is available at www.oxfordbiomedica.co.uk